Precision Care Companion (PCC) enhances biomarker testing and precision therapy adoption in community oncology, uniting practices, labs, and biopharma for improved patient outcomes. PCC focuses on ...

Early disclosure of AD blood biomarker results increases diagnostic certainty and leads to earlier, more targeted clinical ...

We tried out one of the most advanced baseline diagnostic panels available – here’s what we discovered about our health with this biomarker testing… Preventative healthcare has long been the preserve ...

Background: Biomarker testing is essential for guiding first-line treatment decisions in metastatic non–small cell lung cancer (mNSCLC). Despite guideline recommendations, real-world testing patterns ...

Learn why comprehensive biomarker testing is essential before starting any lung cancer treatment. Hear from patients and oncologists about the life-changing importance of knowing your mutation first.

Please provide your email address to receive an email when new articles are posted on . Time from biopsy to receipt of molecular testing results decreased, but most of the improvement occurred at the ...

In this segment, Dr. Alexander Spira and Dr. Edward Kim discuss the critical role of early and comprehensive biomarker testing in the management of early-stage EGFR-mutated non–small cell lung cancer ...

Optum and Illumina Inc. researchers documented that less than half of patients with newly diagnosed advanced cancers received any biomarker testing before starting treatment, a gap that persisted ...

This opening segment frames how first-line management of EGFR-mutated advanced non-small cell lung cancer has shifted from a single-agent standard to several guideline-preferred regimens, each ...

This article is based on a poster originally authored by Rania Gaspo, Renaud Burrer, Jérôme Sallette, Amanda Finan-Marchi, and Marie Gérus-Durand. NSCLC (non-small cell lung cancer) treatment is ...

Across all cancer types, less than 50% of patients underwent biomarker testing before first-line treatment. Many patients with advanced cancer do not receive guideline-recommended biomarker testing ...

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...